Claire Brillac
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Dec 02, 2025
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.Claire Brillac, Dorothée Sémiond, Corina Oprea
|Mar 31, 2022
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu
|Jun 29, 2021
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.Kimiko Koiwai, Raouf El-Cheikh, Hoai-Thu Thai
|May 13, 2021
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin
|Oct 13, 2020
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.Stéphanie Decary, Pierre-François Berne, Céline Nicolazzi
Pageof 1
